Neurostimulation shows promise as potential Alzheimer’s treatment in preliminary trial

Repeated sessions of electrical stimulation to brain networks associated with memory improved verbal learning in some Alzheimer’s disease patients for up to eight weeks in a preliminary trial led by UT Southwestern Medical Center researchers. The findings, published in The Journal of Prevention of Alzheimer’s Disease, indicate that while future trials are needed, neurostimulation shows early promise as a treatment for Alzheimer’s and other neurodegenerative disorders, such as Lewy body dementia.

Levels of select vitamins and minerals in pregnancy may be linked to lower midlife blood pressure risk

Women with higher levels of essential minerals circulating in their blood during pregnancy, particularly copper and manganese, along with vitamin B12, had a lower risk of developing high blood pressure in middle age, about 20 years later, according to research presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2025. The meeting is being held in New Orleans, March 6–9, 2025, and offers the latest science on population-based health and wellness and implications for lifestyle.

High temperatures could affect brain function in preadolescents

Exposure to high ambient temperatures is associated with lower connectivity in three brain networks in preadolescents, suggesting that heat may impact brain function. This is the conclusion of a study led by the Barcelona Institute for Global Health (ISGlobal) and IDIBELL, in collaboration with Erasmus University Medical Center Rotterdam (ERASMUS MC) and the Networked Biomedical Research Center (CIBER): areas of Epidemiology and Public Health (CIBERESP), and Mental Health (CIBERSAM). The results have been published in the Journal of the American Academy of Child & Adolescent Psychiatry.

Chemo-immunotherapy approach shows potential benefit in patients with advanced HPV-negative head and neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.